Changes in saliva secretion and accommodation width during short-term administration of imipramine and zimelidine in healthy volunteers.
Imipramine at a dose of 75 mg/day, the corresponding dose of zimelidine (100 mg/day) and the full therapeutic dose of zimelidine (200 mg/day) were compared with regard to their anti-cholinergic properties. 20 healthy volunteers participated in a double-blind, controlled, randomized cross-over trial and the effects were evaluated by means of a self-rating scale as well as objective measurements of accommodation width and salivary secretion rate. The test-retest reliability of the methods used was quite satisfactory. The full therapeutic dose (200 mg/day) of the new compound zimelidine could be given in one single dose in the morning without causing more pronounced anti-cholinergic effects than the reference compound imipramine which was given at 25-mg doses three times daily.
D000065:Accommodation, Ocular / Q000187:drug effects*; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D001977:Brompheniramine / Q000009:adverse effects* / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects*; D008297:Male; D010275:Parasympathetic Nervous System / Q000187:drug effects; D011725:Pyridines / Q000009:adverse effects*; D012472:Salivation / Q000187:drug effects*; D014987:Xerostomia / Q000139:chemically induced; D015031:Zimeldine
D000928:Antidepressive Agents; D011725:Pyridines; D015031:Zimeldine; D001977:Brompheniramine; D007099:Imipramine